These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34398356)

  • 61. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE.
    Schottelius M; Šimeček J; Hoffmann F; Willibald M; Schwaiger M; Wester HJ
    EJNMMI Res; 2015; 5():22. PubMed ID: 25918675
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas.
    Skoura E; Priftakis D; Novruzov F; Caplin ME; Gnanasegaran G; Navalkissoor S; Bomanji J
    Nucl Med Commun; 2020 Feb; 41(2):169-174. PubMed ID: 31895260
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of
    Hou J; Long T; He Z; Zhou M; Yang N; Chen D; Zeng S; Hu S
    EJNMMI Res; 2021 Jun; 11(1):55. PubMed ID: 34106351
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
    Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
    Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
    Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
    Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in
    Jiménez-Franco LD; Glatting G; Prasad V; Weber WA; Beer AJ; Kletting P
    J Nucl Med; 2021 Jan; 62(1):92-98. PubMed ID: 32646878
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators.
    Tworowska I; Ranganathan D; Thamake S; Delpassand E; Mojtahedi A; Schultz MK; Zhernosekov K; Marx S
    Nucl Med Biol; 2016 Jan; 43(1):19-26. PubMed ID: 26702783
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A PBPK model for PRRT with [
    Vasić V; Gustafsson J; Nowshahr EY; Stenvall A; Beer AJ; Gleisner KS; Glatting G
    Phys Med; 2024 Mar; 119():103299. PubMed ID: 38367588
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
    Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
    J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
    Deppen SA; Blume J; Bobbey AJ; Shah C; Graham MM; Lee P; Delbeke D; Walker RC
    J Nucl Med; 2016 Jun; 57(6):872-8. PubMed ID: 26769864
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
    Meirovitz A; Shouchane-Blum K; Maly A; Bersudski E; Hirshoren N; Abrams R; Popovtzer A; Orevi M; Weinberger J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1335-1340. PubMed ID: 33598797
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Should
    Babazadeh NT; Schlund DJ; Cornelius T; Singh JS; Tierney JF; Chen M; Keutgen XM
    World J Surg; 2020 Feb; 44(2):604-611. PubMed ID: 31576440
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.
    Krauss M; Burghaus R; Lippert J; Niemi M; Neuvonen P; Schuppert A; Willmann S; Kuepfer L; Görlitz L
    In Silico Pharmacol; 2013; 1():6. PubMed ID: 25505651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.